Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice

Synapse

Volumn 35, Issue 4, 2000, Pages 250-255

  Kilbourn, Michael R ^a,b   Kuszpit, Kyle ^a   Sherman, Phillip ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Methylphenidate; Neurodegeneration; Tetrabenazine

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE TRANSPORTER; METHYLPHENIDATE; RADIOLIGAND; TETRABENAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; ENZYME ACTIVITY; LIGAND BINDING; MALE; MOUSE; NERVE CELL MEMBRANE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STRIATE CORTEX;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; CARBON RADIOISOTOPES; CARRIER PROTEINS; CEREBELLUM; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HIPPOCAMPUS; HYPOTHALAMUS; KINETICS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHYLPHENIDATE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; RADIOLIGAND ASSAY; TETRABENAZINE; TISSUE DISTRIBUTION; TRITIUM; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0033966874     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(20000315)35:4<250::AID-SYN2>3.0.CO;2-S     Document Type: Article

References (32)

1. 11C]methylphenidate for studying presynaptic dopaminergic neuron with positron emission tomography. J Labeled Compd Radiopharm 34:989-997.
2. Donnan GA, Kaczmarczyk SJ, McKenzie JS, Rowe, PJ, Kalnins RM, Mendelsohn FAO. 1987. Regional and temporal effects of 1-methyl-1,2,3,6-tetrahydropyridine on dopamine uptake sites in mouse brain. J Neurol Sci 81:261-271.
3. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE. 1996. Presynaptic monoamine vesicles in Parkinson's disease and normal aging. Ann Neurol 40:873-884.
4. Frey K, Kilbourn M, Robinson T. 1997. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol 334:273-279.
5. +-induced effects on body temperature exhibit age-and strain-dependence in mice. Brain Res 688:161-170.
6. Freyaldenhoven TE, Ali SF, Schmued LC. 1997. Systemic administration of MPTP induces thalamic neuronal degeneration in mice. Brain Res 759:9-17.
7. 11C]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine. Eur J Pharmacol 281:141-149.
8. Gelrach M, Riederer P. 1991. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041.
9. 3H]-DTBZ binding in striata of methamphetamine (METH)-treated mice. Soc Neurosci Abstr 24:1481.
10. Hoskins JA, Davies LJ. 1989. The acute effect on levels of catecholamines and metabolites in brain, of a single dose of MPTP in 8 strains of mice. Neuropharmacology 28:1389-1397.
11. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4:257-269.
12. 11C]dihydrotetrabenazine. Appl Rad Isot 24:197-199.
13. Jossan SS, Sakurai E, Oreland L. 1989. MPTP toxicity in relation to age, dopamine uptake and MAO-B activity in two rodent species. Pharmacol Toxicol 64:314-318.
14. Kilbourn MR. 1997. In vivo radiotracers for vesicular neurotransmitter transporters. Nucl Med Biol 24:615-619.
15. 3H]dihydrotetrabenazine to the vesicular monoamine transporter of rat brain: bolus vs. equilibrium studies. Eur J Pharmacol 331:161-168.
16. 18F]GBR 13119 in MPTP-treated C57BL/6 mice. Nucl Med Biol 18:803-, 806.
17. Kilbourn MR, Lee L, Vander Borght T, Jewett D, Frey K. 1995. Binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol 278:249-252.
18. Kilbourn MR, Sherman P, Abbott LC. 1998. Reduced MPTP neurotoxicity in the striatum of the mutant mouse tottering. Synapse 20:205-210.
19. Mitsumoto Y, Watanabe A, Mori A, Koga N. 1998. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem Biophys Res Comm 248:660-663.
20. Pileblad E, Carlsson A. 1988. Studies on the acute and long-term changes in dopamine and noradrenaline metabolism in mouse brain following administration of 1-methyl-1,2,3,6-tetrahydropyridine (MPTP). Pharmacol Toxicol 62:213-222.
21. Pileblad E, Fornstedt B, Clark D, Carlsson A. 1985. Acute effects of 1-methyl-1,2,3,6-tetrahydropyridine on dopamine metabolism in mouse and rat striatum. J Pharm Pharmacol 37:707-712.
22. Ricuarte GA, DeLanney LE, Irwin I, Langston JW. 1987. Older dopaminergic neurons do not recover from the effects of MPTP. Neuropharmacology 26:97-99.
23. Saitoh T, Niijima K, Mizuno Y. 1987. Long-term effect of 1-methyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine content in young and mature mice. J Neurol Sci 77:229-235.
24. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y, 1989. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 26:551-557.
25. Vaglini F, Fascetti F, Tedeschi D, Cavalletti M, Fornai F, Corsini GC. 1996. Striatal MPP levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice. Neurodegeneration 5:129-136.
26. 3H]Methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 68:955-962.
27. Vander Borght TM, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA. 1995b. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294:577-583.
28. Wilson JMKish SJ. 1996. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 16:3507-3510.
29. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ. 1996a. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Med 2:699-703.
30. Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, Adams VI, Smialek J, Anderson WR, Shannak K, Deck J, Niznik HB, Kish SJ. 1996b. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 40:428-439.
31. Wilson JM, Levey AI, Rajput A, Ang L, Guttman M, Shannak K, Niznik HB, Hornykiewicz O, Pifl C, Kish SJ. 1996c. Differential changes in neurochemical markers of Striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47:718-726.
32. Zigmond MJ. 1997. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? insights from an animal model of parkinsonism. Neurobiol Dis 4:247-253.